Columbia Labs
This article was originally published in The Tan Sheet
Executive Summary
Firm expands sales force to 135 people and is deploying group to detail its women's healthcare products. Offerings include Advantage-S spermicidal contraceptive and RepHresh Vaginal Gel marketed to OB/GYNs and other professional audiences, President & CEO Fred Wilkinson announces in Aug. 7 earnings call. The OTC products' Q2 sales helped boost Columbia's net revenues 36% to $4.9 mil. over Q1. Wilkinson predicts increased sales efforts behind Columbia's present products and launch of Rx Striant testosterone buccal system - which FDA approved June 19 - will allow the company to garner earnings, cash positive numbers by year end. Columbia posted a $4.4 mil. net loss in the second quarter...